List of Excipients in Branded Drug HALOETTE

Generic Drugs Containing HALOETTE

Company	Ingredient	NDC	Excipient
Mayne Pharma Inc	etonogestrel and ethinyl estradiol	51862-148	ETHYLENE-VINYL ACETATE COPOLYMER
Mayne Pharma Inc	etonogestrel and ethinyl estradiol	51862-148	MAGNESIUM STEARATE
Dr Reddy's Labratories Inc	etonogestrel and ethinyl estradiol	75907-088	ETHYLENE-VINYL ACETATE COPOLYMER

What are the Most Frequently-Used Excipients in HALOETTE?

# Of NDCs	Excipient
2	ETHYLENE-VINYL ACETATE COPOLYMER
2	MAGNESIUM STEARATE

Haloette Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Haloette is a generic etonogestrel/ethinyl estradiol vaginal ring used for contraception. Its commercial value depends less on new active-ingredient claims than on manufacturing cost, release-rate control, polymer sourcing, packaging stability, patient access, and private-label distribution. The core excipient platform is an ethylene-vinyl acetate polymer ring containing magnesium stearate as a processing or release-related component.[1]

The most practical opportunities are supply-chain optimization, polymer-grade qualification, differentiated packaging, geographic expansion, and line extensions that remain within the established vaginal-ring regulatory framework. A new excipient or materially different release profile would increase regulatory and bioequivalence risk.

What is Haloette and which excipients does it contain?

Haloette contains etonogestrel and ethinyl estradiol in a flexible vaginal ring. The ring releases approximately 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week use period, subject to product-label instructions.[1]

Attribute	Haloette
Active ingredients	Etonogestrel and ethinyl estradiol
Dosage form	Vaginal ring
Route	Intravaginal
Contraceptive class	Combined hormonal contraceptive
Typical use period	Three weeks inserted, followed by a ring-free interval
Principal polymer	Ethylene-vinyl acetate copolymer
Other disclosed excipient	Magnesium stearate
Reference product	NuvaRing
FDA pathway	Abbreviated New Drug Application
Product type	Small-molecule generic, not a biologic
Commercial status	Prescription contraceptive vaginal ring

The polymer is the functional excipient. It determines mechanical integrity, drug diffusion, surface characteristics, flexibility, residual drug content, and release kinetics. Magnesium stearate is present in the formulation and can affect processing, dispersion, and the microstructure of the drug-polymer matrix.[1]

How does Haloette’s excipient system control drug release?

The ring uses a matrix-reservoir design in which the steroid hormones are dispersed within an ethylene-vinyl acetate polymer. Release occurs primarily through diffusion from the polymer into the vaginal environment.

The key formulation variables are:

1. Vinyl acetate content and polymer grade.
2. Molecular weight and melt-flow characteristics.
3. Drug loading and distribution.
4. Magnesium stearate concentration and particle-size distribution.
5. Ring diameter, cross-sectional geometry, and surface area.
6. Extrusion temperature, residence time, and cooling conditions.
7. Residual solvent, moisture, and volatile content.
8. Packaging conditions during storage.

Small changes in polymer composition can alter the release rate of both hormones. Etonogestrel and ethinyl estradiol do not necessarily diffuse through the matrix at the same rate. A formulation that changes the polymer’s polarity, crystallinity, or free volume can create a disproportionate impact on one active ingredient.

Excipient attributes with the highest commercial value

Excipient or process attribute	Commercial effect	Regulatory sensitivity
Ethylene-vinyl acetate grade	Controls release, flexibility, and extrusion performance	High
Polymer supplier qualification	Reduces supply interruption and cost	High
Magnesium stearate dispersion	Affects uniformity and processing	Medium to high
Particle size of magnesium stearate	Influences blend homogeneity and matrix structure	Medium
Polymer melt flow	Affects tooling, throughput, and ring geometry	High
Extractables and leachables profile	Determines packaging and safety burden	High
Residual monomers and volatiles	Affects toxicology and stability assessments	High
Colorants or surface modifiers	May improve identification or acceptability	Medium to high

What excipient strategies are available for Haloette?

1. Dual-source ethylene-vinyl acetate

The strongest near-term strategy is qualification of two or more pharmaceutical-grade ethylene-vinyl acetate sources. A second source can reduce exposure to polymer shortages, supplier pricing, and manufacturing-site interruptions.

The principal risk is that nominally equivalent polymer grades may not be functionally equivalent. The manufacturer should compare:

• Vinyl acetate content.
• Molecular-weight distribution.
• Melt-flow rate.
• Density and crystallinity.
• Residual monomers.
• Heavy metals and elemental impurities.
• Drug-release profiles.
• Mechanical strength after accelerated aging.

A supplier change that affects release kinetics may require regulatory notification, supplemental studies, or a new bioequivalence assessment.

2. Process optimization without excipient substitution

Process changes are usually more defensible than introducing a new functional excipient. Opportunities include:

• Improved premixing of hormone powders and polymer.
• Lower-temperature extrusion to limit degradation.
• Tighter control of residence time.
• Reduced scrap and rework.
• Automated ring-diameter inspection.
• Inline weight and dimensional controls.
• Better cooling and annealing conditions.

This approach can lower cost while preserving the qualitative and quantitative composition required for an ANDA product.

3. Magnesium stearate optimization

Magnesium stearate can be optimized for particle size, surface area, and dispersion. The commercial objective is to improve processing consistency without changing the release profile.

Potential benefits include lower batch variability, improved extrusion throughput, and reduced adhesion to tooling. The formulation team must control over-lubrication, which can affect polymer wetting, active-ingredient distribution, and release.

4. Alternative polymer systems

A substitute for ethylene-vinyl acetate could create meaningful intellectual-property and product-differentiation opportunities, but it would also create the highest regulatory risk. Candidate systems could include other medically accepted elastomeric or thermoplastic polymers, multilayer structures, or coated matrices.

A polymer substitution would require a complete assessment of:

• Hormone release over the labeled use period.
• Local vaginal tolerability.
• Mechanical failure and fragmentation.
• Extractables and leachables.
• Residual monomers.
• Sterility or bioburden controls, where applicable.
• Packaging compatibility.
• Human pharmacokinetic comparability.

For a generic product, a materially different polymer may undermine the ANDA strategy if the product no longer qualifies as the same dosage form and formulation under FDA requirements.[2]

What formulations are protected by Haloette or NuvaRing patents?

The historical patent estate for NuvaRing concentrated on the vaginal-ring delivery system, hormone-containing polymer matrix, controlled release, and use of the ring for contraception. The active ingredients themselves are old, and the principal competitive barrier has been formulation and delivery-system protection rather than composition-of-matter exclusivity.

Protection category	Relevance to Haloette	Commercial implication
Etonogestrel composition patents	Limited; active ingredient is established	Low barrier
Ethinyl estradiol composition patents	Limited; active ingredient is established	Low barrier
Hormone-polymer matrix	High	Can affect formulation design
Vaginal-ring geometry	Medium to high	May constrain design-around options
Controlled-release claims	High	Central to generic development
Contraceptive method-of-use claims	Medium	Relevant to labeling and litigation
Packaging and storage claims	Variable	Can support lifecycle management
Manufacturing-process claims	Variable	Can create source-specific barriers

The major patent barriers associated with the original NuvaRing product were generally approaching or reaching expiration by the period in which generic vaginal rings entered the U.S. market. The commercial significance of any remaining patent depends on its claims, terminal disclaimers, pediatric extensions, Orange Book listing, litigation history, and enforceability.

A formulation developer should treat the polymer composition and release profile as the primary freedom-to-operate issues. Avoiding a listed patent does not eliminate risk if the alternative design produces substantially the same claimed structure or release function.

What is the Orange Book status of Haloette?

Haloette is an ANDA product. FDA Orange Book listings for generic products generally identify the reference listed drug and any applicable patent certifications, but the patent listings for the reference product do not necessarily transfer to the generic product as separate Haloette patents.[3]

The relevant regulatory questions are:

• Which reference product is identified for Haloette?
• What patent certifications were submitted with the ANDA?
• Were Paragraph IV certifications made?
• Was a 30-month stay triggered?
• Are any pediatric exclusivity periods relevant?
• Are any method-of-use patents carved out of the labeling?
• Is the current label consistent with the reference product?

For Haloette, the relevant regulatory exposure is associated with the reference product’s listed patents and the ANDA certification history. Generic approval indicates that FDA accepted the ANDA’s pharmaceutical equivalence, bioequivalence, manufacturing controls, and labeling position. It does not eliminate the possibility of patent litigation outside the approval decision.

When did Haloette lose exclusivity, and when can generic competition enter?

The reference product NuvaRing was approved in the U.S. in 2001. Haloette entered the market through the generic pathway after the principal commercial protection period for NuvaRing had substantially weakened.[1][3]

Milestone	Approximate timing
NuvaRing U.S. approval	2001
Original formulation and delivery patents	Expired or reached late-life status during the 2010s and early 2020s
Generic vaginal-ring development	Accelerated after core patent barriers declined
Haloette generic approval period	Late 2010s
Current competitive issue	Price, supply, payer access, and patient adoption

The timing of commercial entry is not determined by patent expiration alone. FDA exclusivity, Paragraph IV litigation, settlement agreements, manufacturing readiness, and launch-at-risk decisions can change the effective entry date.

Which companies are challenging the NuvaRing market?

The U.S. vaginal-ring market includes the originator NuvaRing and generic products such as Haloette and other etonogestrel/ethinyl estradiol rings. Competition is concentrated among:

• Originator and affiliated commercial partners.
• Generic manufacturers with ANDA approvals.
• Contract manufacturers with vaginal-device extrusion capability.
• Private-label distributors.
• Digital contraception platforms and specialty pharmacies.

The principal entry barrier is not active-ingredient synthesis. It is reliable manufacture of a small, hormone-loaded polymer ring with consistent release and acceptable mechanical performance.

Generic manufacturers can compete through:

• Lower acquisition cost.
• Medicaid and managed-care contracting.
• Private-label arrangements.
• Retail pharmacy distribution.
• Specialty contraceptive programs.
• Patient-support services.
• Contract manufacturing for regional markets.

What licensing deals affect Haloette?

Public FDA materials identify the product, formulation, labeling, and regulatory pathway, but they do not establish a broad licensing framework for Haloette. Commercial rights may involve manufacturing, distribution, private-label, or marketing arrangements that are not fully visible in FDA records.

The most valuable licensing opportunities are likely to involve:

1. Regional marketing rights.
2. Private-label supply.
3. Polymer technology.
4. Vaginal-ring extrusion technology.
5. Packaging systems.
6. Improved hormone-loading or release-control processes.
7. International regulatory dossiers.

A polymer or manufacturing license can have greater strategic value than a license to the active ingredients because the process is the operational bottleneck.

How strong is Haloette’s patent estate?

Haloette is more exposed to operational and commercial competition than to a broad proprietary patent moat.

Factor	Assessment
Active-ingredient protection	Weak
Core delivery-system differentiation	Limited for a generic product
Excipient platform defensibility	Moderate if process-specific
Manufacturing know-how	Moderate to strong
Regulatory complexity	Moderate to high
Switching cost for pharmacies	Low
Patient switching cost	Moderate because insertion, removal, and bleeding patterns matter
Supply-chain barrier	Meaningful
Biosimilar barrier	None

The strongest defensible assets are likely to be confidential manufacturing know-how, validated polymer specifications, process controls, tooling, stability data, and supplier relationships. These assets can support commercial advantage even where patent protection is limited.

What generic launch risks exist for Haloette?

Patent and litigation risk

Paragraph IV litigation can delay approval or create launch-at-risk exposure. The most relevant disputes would involve ring structure, hormone-polymer composition, controlled release, or use claims.

Regulatory risk

A formulation change can trigger questions about pharmaceutical equivalence, bioequivalence, inactive-ingredient safety, and release comparability. FDA guidance for ANDA development places substantial importance on sameness and product quality for complex dosage forms.[2]

Manufacturing risk

Vaginal rings require tight control of drug distribution and dimensions. Common failure points include:

• Nonuniform active-ingredient loading.
• Ring deformation.
• Surface defects.
• Inconsistent release.
• Polymer degradation.
• Tooling contamination.
• Packaging-induced changes.
• Supplier variability.

Commercial risk

The market can experience rapid price erosion after multiple generic entrants. A manufacturer with only one customer or one distributor may lose volume even if its product remains approved.

What commercial opportunities exist beyond the base Haloette product?

Private-label contraceptive rings

Private-label supply can expand volume without requiring a separate clinical development program. The supplier must control branding, packaging, labeling, pharmacovigilance, and allocation of regulatory responsibilities.

International expansion

The same polymer platform may support registrations in markets that recognize U.S. data or accept abbreviated applications. Requirements differ for:

• Vaginal-device classification.
• Hormonal contraceptive labeling.
• Local bioequivalence.
• Packaging language.
• Pharmacovigilance.
• Prescription or nonprescription status.

Packaging differentiation

Packaging can improve shelf stability, portability, and pharmacy handling. Opportunity areas include moisture-barrier materials, child-resistant systems, discreet packaging, and unit-dose configurations. Any new package must be evaluated for extractables, leachables, moisture transmission, and product stability.

Next-generation ring products

A manufacturer could pursue rings with longer wear periods, different hormone combinations, or alternative release profiles. These products would generally require a more substantial clinical and regulatory program than Haloette and should be treated as separate lifecycle products rather than simple excipient modifications.

Manufacturing-as-a-service

Companies with validated vaginal-ring extrusion capacity can offer contract development and manufacturing to regional pharmaceutical firms. The value proposition is strongest where the customer lacks polymer-processing, hormone-handling, and release-testing capabilities.

Key Takeaways

• Haloette is an etonogestrel/ethinyl estradiol vaginal ring using an ethylene-vinyl acetate polymer matrix with magnesium stearate.
• The polymer is the main functional excipient and the central source of release-rate and manufacturing risk.
• The best near-term strategy is polymer dual sourcing, process optimization, and tighter control of release-critical attributes.
• A new polymer or materially different excipient system could create differentiation but would increase FDA, bioequivalence, stability, and patent risk.
• The product has limited active-ingredient patent protection and a weaker patent moat than an innovative drug.
• Manufacturing know-how, supply reliability, packaging, private-label distribution, and regional licensing are the main commercial opportunities.
• Haloette has no biosimilar risk because it is a small-molecule generic, not a biologic.
• Generic price erosion, Paragraph IV disputes, polymer supply, and release-profile variability are the main risks.

FAQs

Is ethylene-vinyl acetate safe for a contraceptive vaginal ring?

Ethylene-vinyl acetate is an established medical polymer, but safety depends on grade, residual monomers, extractables, leachables, manufacturing controls, and the final product’s local tolerability profile.

Can Haloette use a different polymer from NuvaRing?

A different polymer may be possible for a new product, but it can undermine the ANDA sameness strategy and require additional release, safety, stability, and bioequivalence evidence.

Does magnesium stearate control the contraceptive effect of Haloette?

Magnesium stearate is not the contraceptive active ingredient. Its concentration and dispersion can still affect processing and the physical structure of the polymer matrix, which may influence hormone release.

Could Haloette become an over-the-counter contraceptive?

An OTC switch would require FDA review of consumer-use data, labeling comprehension, self-selection, and safe-use conditions. It would be a regulatory lifecycle strategy rather than an excipient change.

What is the most valuable Haloette manufacturing asset?

The most valuable asset is usually a validated, scalable process that consistently produces hormone-loaded rings meeting dimensional, mechanical, assay, content-uniformity, release, and stability specifications.

References

1. U.S. Food and Drug Administration. (2019). Haloette: Etonogestrel and ethinyl estradiol vaginal ring prescribing information.
2. U.S. Food and Drug Administration. (2016). ANDAs for certain highly purified synthetic peptide drug products that reference listed drugs of recombinant origin: Guidance for industry.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2001). NuvaRing: Etonogestrel and ethinyl estradiol vaginal ring approval documentation and prescribing information.